Payment overview · 2025
General Payments
$411.31
16 reported records · 10 companies
Healthcare provider profile · identity verified
Irma V Lopez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JUPITER, FL · NPI 1194778274
Verified facts
What the public records show
CMS Open Payments records show Irma V Lopez, M.D. received $411.31 in general payments during 2025 across 16 reported records.
Eisai Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.99 | 30.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $47.62 | 11.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.80 | 10.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.99 | 10.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.73 | 8.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.08 | 8.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.80 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.14 | 5.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.07 | 3.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.09 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.31 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.80 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 43 |
| Alendronate Sodium | Alendronate Sodium | 99 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 34 |
| Trazodone Hcl | Trazodone Hcl | 82 | 32 |
| Eliquis | Apixaban | 78 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 31 |
| Azithromycin | Azithromycin | 75 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 27 |
| Methylprednisolone | Methylprednisolone | 72 | 56 |
| Metformin Hcl | Metformin Hcl | 70 | 24 |
| Alprazolam | Alprazolam | 66 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 64 | 48 |
| Losartan Potassium | Losartan Potassium | 62 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 17 |
| Omeprazole | Omeprazole | 58 | 25 |
| Cefdinir | Cefdinir | 55 | 45 |
| Sertraline Hcl | Sertraline Hcl | 48 | 16 |
| Furosemide | Furosemide | 47 | 19 |
| Gabapentin | Gabapentin | 47 | 21 |
| Ezetimibe | Ezetimibe | 46 | 19 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 17 |
| Lisinopril | Lisinopril | 41 | 12 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 14 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Meloxicam | Meloxicam | 30 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 16 |
| Synthroid | Levothyroxine Sodium | 29 | 11 |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Ozempic | Semaglutide | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Bupropion Xl | Bupropion Hcl | 27 | 15 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 16 |
| Tramadol Hcl | Tramadol Hcl | 23 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Prednisone | Prednisone | 20 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 15 |
| Simvastatin | Simvastatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Diazepam | Diazepam | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.31 · 16 records | Eisai Inc. | Arikayce, Brinsupri, CAPVAXIVE, Cologuard Collection Kit, ENTRESTO, JARDIANCE, KISUNLA, LEQVIO, Leqembi, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error